Clinical Trial Update: Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study [Phase 2]

View source ↗

Summary

Phase 2 PRISM trial uses biomarker tests to guide selection of personalized therapies for extensive-stage small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Status: RECRUITING